Showing results (751-760 of 1,321) with videos related to

Sort By:
Pageof 133
Biochimie|September 24, 2009
Modulation of the hepatic fatty acid pool in peroxisomal 3-ketoacyl-CoA thiolase B-null mice exposed to the selective PPARalpha agonist Wy14,643Ségolène Arnauld, Marco Fidaleo, Marie-Claude Clémencet, et al.
Journal of Cellular Physiology|March 9, 2005
Functional analysis of TMLH variants and definition of domains required for catalytic activity and mitochondrial targetingJlenia Monfregola, Armando Cevenini, Antonio Terracciano, et al.
Frontiers in Cell and Developmental Biology|April 19, 2021
Autophagy Inhibitors Do Not Restore Peroxisomal Functions in Cells With the Most Common Peroxisome Biogenesis DefectFemke C C Klouwer, Kim D Falkenberg, Rob Ofman, et al.
American Journal of Medical Genetics. Part A|October 18, 2008
Carnitine-palmitoyltransferase 2 deficiency: novel mutations and relevance of newborn screeningSabine Illsinger, Thomas Lücke, Michael Peter, et al.
Molecular and Cellular Biology|June 25, 1998
PEX12, the pathogenic gene of group III Zellweger syndrome: cDNA cloning by functional complementation on a CHO cell mutant, patient analysis, and characterization of PEX12pK Okumoto, N Shimozawa, A Kawai, et al.
Investigational New Drugs|November 6, 2004
A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancerFrancesco Caponigro, Pax Willemse, Roberto Sorio, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|June 28, 2019
Infectivity and stability of hepatitis C virus in different perfusion solutionsFabian A Helfritz, Verena Wanders, Denisa Bojkova, et al.
Journal of Medical Genetics|October 21, 1999
Defective PEX gene products correlate with the protein import, biochemical abnormalities, and phenotypic heterogeneity in peroxisome biogenesis disordersN Shimozawa, A Imamura, Z Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 1996
Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive daysI Wolff, K Bench, J H Beijnen, et al.
Investigational New Drugs|August 21, 2008
Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820Ron J Keizer, Miren K Zamacona, Mendel Jansen, et al.
Pageof 133